Isis begins Phase II in psoriasis

ISIP began a double-blind, placebo-controlled U.S. Phase II trial of ISIS 104838, an oral formulation of an antisense inhibitor of TNF-alpha to treat psoriasis. The 60-patient study will assess the ab...